Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where authors phrase all words ' Flockhart, DA' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 84 riferimenti
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Rosebraugh, CJ; Flockhart, DA; Yasuda, SU; Woosley, RL
      Olanzapine-induced rhabdomyolysis

      ANNALS OF PHARMACOTHERAPY
    2. Tanus-Santos, JE; Desai, M; Flockhart, DA
      Effects of ethnicity on the distribution of clinically relevant endothelial nitric oxide variants

      PHARMACOGENETICS
    3. Desta, Z; Kivisto, KT; Lilja, JJ; Backman, JT; Soukhova, N; Neuvonen, PJ; Flockhart, DA
      Stereoselective pharmacokinetics of cisapride in healthy volunteers and the effect of repeated administration of grapefruit juice

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    4. Shin, JG; Kane, K; Flockhart, DA
      Potent inhibition of CYP2D6 by haloperidol metabolites: stereoselective inhibition by reduced haloperidol

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    5. Rosebraugh, CJ; Honig, PK; Yasuda, SU; Pezzullo, JC; Flockhart, DA; Woosley, RL
      Formal education about medication errors in internal medicine clerkships

      JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
    6. Rosebraugh, CJ; Flockhart, DA; Yasuda, SU; Woosley, RL
      Visual hallucination and tremor induced by sertraline and oxycodone in a bone marrow transplant patient

      JOURNAL OF CLINICAL PHARMACOLOGY
    7. Desta, Z; Soukhova, NV; Flockhart, DA
      Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: Potent inhibition of CYP2C19 and CYP3A

      ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
    8. Rae, JM; Johnson, MD; Lippman, ME; Flockhart, DA
      Rifampin is a selective, pleiotropic inducer of drug metabolism genes in human hepatocytes: Studies with cDNA and oligonucleotide expression arrays

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    9. Desta, Z; Soukhova, N; Morocho, AM; Flockhart, DA
      Stereoselective metabolism of cisapride and enantiomer-enantiomer interaction in human cytochrome P450 enzymes: Major role of CYP3A

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    10. Desta, Z; Soukhova, NV; Morocho, A; Park, J; Mahal, SK; Flockhart, DA
      Stereoselective determination of cisapride, a prokinetic agent, in human plasma by chiral high-performance liquid chromatography with ultraviolet detection: application to pharmacokinetic study

      JOURNAL OF CHROMATOGRAPHY B
    11. Flockhart, DA; Oesterheld, JR
      Cytochrome P450-mediated drug interactions

      CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA
    12. Abbas, R; Chow, CP; Browder, NJ; Thacker, D; Bramer, SL; Fu, CJ; Forbes, W; Odomi, M; Flockhart, DA
      In vitro metabolism and interaction of cilostazol with human hepatic cytochrome P450 isoforms

      HUMAN & EXPERIMENTAL TOXICOLOGY
    13. Flockhart, DA; Desta, Z; Mahal, SK
      Selection of drugs to treat gastro-oesophageal reflux disease - The role of drug interactions

      CLINICAL PHARMACOKINETICS
    14. Williams, ML; Bhargava, P; Cherrouk, I; Marshall, JL; Flockhart, DA; Wainer, IW
      A discordance of the cytochrome P4502C19 genotype and phenotype in patients with advanced cancer

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    15. Ko, JW; Desta, Z; Soukhova, NV; Tracy, T; Flockhart, DA
      In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: potent effect on CYP2C19 and CYP2D6

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    16. Flockhart, DA; Drici, MD; Kerbusch, T; Soukhova, N; Richard, E; Pearle, PL; Mahal, SK; Babb, VJ
      Studies on the mechanism of a fatal clarithromycin-pimozide interaction ina patient with Tourette syndrome

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    17. Desta, Z; Soukhova, N; Mahal, SK; Flockhart, DA
      Interaction of cisapride with the human cytochrome P450 system: Metabolismand inhibition studies

      DRUG METABOLISM AND DISPOSITION
    18. Yoon, YR; Cha, IJ; Shon, JH; Lim, KA; Cha, YN; Jang, IJ; Park, CW; Shin, SG; Flockhart, DA; Shin, JG
      Relationship of paroxetine disposition to metoprolol metabolic ratio and CPsi P2D6*10 genotype of Korean subjects

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    19. Benton, RE; Sale, M; Flockhart, DA; Woosley, RL
      Greater quinidine-induced QTc interval prolongation in women

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    20. Abernethy, DR; Flockhart, DA
      Molecular basis of cardiovascular drug metabolism - Implications for predicting clinically important drug interactions

      CIRCULATION
    21. Xie, HG; Stein, CM; Kim, RB; Wilkinson, GR; Flockhart, DA; Wood, AJJ
      Allelic, genotypic and phenotypic distributions of S-mephenytoin 4 '-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world

      PHARMACOGENETICS
    22. Yuan, R; Flockhart, DA; Balian, JD
      Pharmacokinetic and pharmacodynamic consequences of metabolism-based drug interactions with alprazolam, midazolam, and triazolam

      JOURNAL OF CLINICAL PHARMACOLOGY
    23. Shin, JG; Soukhova, N; Flockhart, DA
      Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: Preferential inhibition of CYP2D6

      DRUG METABOLISM AND DISPOSITION
    24. Desta, Z; Flockhart, DA
      In vitro stability of endogenous gamma-hydroxybutyrate in postmortem blood- Commentary

      JOURNAL OF FORENSIC SCIENCES
    25. Donahue, S; Flockhart, DA; Abernethy, DR
      Ticlopidine inhibits phenytoin clearance

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    26. Ko, JW; Jang, IJ; Shin, JG; Nam, SK; Shin, SG; Flockhart, DA
      Theophylline pharmacokinetics are not altered by lansoprazole in CYP2C19 poor metabolizers

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    27. Desta, Z; Kerbusch, T; Flockhart, DA
      Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6)

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    28. THACKER DL; ABERNETHY DR; RAINES A; FLOCKHART DA
      METHOD FOR THE DETERMINATION OF 5,5-DIPHENYLBARBITURIC ACID AND ITS SEPARATION FROM 1,3-DIMETHOXYMETHYL-5,5-DIPHENYLBARBITURIC ACID IN PLASMA BY HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY

      Journal of chromatography B. Biomedical sciences and applications
    29. Drici, MD; Wang, WX; Liu, XK; Woosley, RL; Flockhart, DA
      Prolongation of QT interval in isolated feline hearts by antipsychotic drugs

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    30. Flockhart, DA; Webb, DJ
      Clinical pharmacology - Blue-chip technology

      LANCET
    31. KO JW; DESTA Z; FLOCKHART DA
      HUMAN N-DEMETHYLATION OF (S)-MEPHENYTOIN BY CYTOCHROME P450S 2C9 AND 2B6

      Drug metabolism and disposition
    32. DESTA Z; KERBUSCH T; SOUKHOVA N; RICHARD E; KO JW; FLOCKHART DA
      IDENTIFICATION AND CHARACTERIZATION OF HUMAN CYTOCHROME-P450 ISOFORMSINTERACTING WITH PIMOZIDE

      The Journal of pharmacology and experimental therapeutics
    33. WANDEL C; LANG CC; COWART DC; GIRARD AF; BRAMER S; FLOCKHART DA; WOOD AJJ
      EFFECT OF CYP3A INHIBITION ON VESNARINONE METABOLISM IN HUMANS

      Clinical pharmacology and therapeutics
    34. MARTIN DE; TRAN JQ; FLOCKHART DA; JORKASKY DK
      ANALYSIS OF CYP2D6 AND CYP2C19 GENOTYPES IN LARGE AFRICAN-AMERICAN (AA) AND, CAUCASIAN (C) POPULATIONS

      Clinical pharmacology and therapeutics
    35. KO JW; SUKHOVA N; OAKES S; FLOCKHART DA
      TICLOPIDINE IS A POTENT INHIBITOR OF CYP2C19 AND CYP2D6 IN-VITRO

      Clinical pharmacology and therapeutics
    36. KO JW; JANG IJ; SHIN SG; FLOCKHART DA
      EFFECT OF LANSOPRAZOLE ON THEOPHYLLINE CLEARANCE IN EXTENSIVE AND POOR METABOLIZERS OF CYTOCHROME-P450 2C19

      Clinical pharmacology and therapeutics
    37. FROHNA PA; MACPHERSON A; FLOCKHART DA
      THE PREVALENCE OF A DOPAMINE-D4 RECEPTOR VARIANT, D4GLYCINE194, IN AFRICAN-AMERICANS AND KOREANS

      Clinical pharmacology and therapeutics
    38. DESTA Z; KERBUSCH T; FLOCKHART DA
      EFFECT OF CLARITHROMYCIN (CLM) ON THE PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF PIMOZIDE (PIM) IN HEALTHY POOR (PM) AND EXTENSIVE (EM) METABOLIZERS OF CYP2D6

      Clinical pharmacology and therapeutics
    39. JACKSON MD; MACPHERSON AS; FLOCKHART DA
      CYP2C9 GENETIC-POLYMORPHISM IN AN AFRICAN-AMERICAN POPULATION

      Clinical pharmacology and therapeutics
    40. ONEIL WM; DIGIROLAMO A; GILFIX BM; FLOCKHART DA; TSOUKAS CM; WAINER IW
      THE GENOTYPE AND EXPRESSED PHENOTYPE OF CYTOCHROME-P450 2D6 AMONG HIV+ AIDS PATIENTS/

      Clinical pharmacology and therapeutics
    41. SHIN JG; SOUKHOVA N; DESTA Z; FLOCKHART DA
      INHIBITION OF CYP2D6 BY ANTIPSYCHOTIC-DRUGS

      Clinical pharmacology and therapeutics
    42. Trapnell, CB; Donahue, SR; Collins, JM; Flockhart, DA; Thacker, D; Abernethy, DR
      Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    43. KERBUSCH T; DESTA Z; SOUKHOVA NV; THACKER D; FLOCKHART DA
      SENSITIVE ASSAY FOR PIMOZIDE IN HUMAN PLASMA USING HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHY WITH FLUORESCENCE DETECTION - APPLICATION TO PHARMACOKINETIC STUDIES

      Journal of chromatography B. Biomedical sciences and applications
    44. BENTON RE; FRANZ M; GLEASON SE; SALE M; FLOCKHART DA; WOOSLEY RL
      GENDER EFFECTS OF QUINIDINE ON QT INTERVAL AND QT DISPERSION

      Journal of the American College of Cardiology
    45. KO JW; SUKHOVA N; THACKER D; CHEN P; FLOCKHART DA
      EVALUATION OF OMEPRAZOLE AND LANSOPRAZOLE AS INHIBITORS OF CYTOCHROME-P450 ISOFORMS

      Drug metabolism and disposition
    46. MOLLER DR; WYSOCKA M; GREENLEE BM; MA XJ; WAHL L; FLOCKHART DA; TRINCHIERI G; KARP CL
      INHIBITION OF IL-12 PRODUCTION BY THALIDOMIDE

      The Journal of immunology
    47. SALCEDO JA; FLOCKHART DA; MAHER KA; SUKHOVA N; BENJAMIN SB
      PHARMACOKINETIC PROFILE OF OMEPRAZOLE AND INTRAGASTRIC PH IN GERD PATIENTS THAT RELAPSE OX MAINTENANCE THERAPY

      Gastroenterology
    48. SALCEDO JA; BENJAMIN SB; MAHER KA; SUKHOVA N; FLOCKHART DA
      ERYTHROMYCIN INHIBITS THE METABOLISM OF OMEPRAZOLE

      Gastroenterology
    49. DONAHUE SR; FLOCKHART DA; ABERNETHY DR; KO JW
      TICLOPIDINE INHIBITION OF PHENYTOIN METABOLISM MEDIATED BY POTENT INHIBITION OF CYP2C19

      Clinical pharmacology and therapeutics
    50. KO JW; SUKHOVA N; THACKER D; CHEN P; FLOCKHART DA
      EVALUATION OF OMEPRAZOLE AND LANSOPRAZOLE AS INHIBITORS OF CYTOCHROME-P450 ISOFORMS

      Clinical pharmacology and therapeutics
    51. KO JW; MACPHERSON AS; JANG IJ; SHIN SG; FLOCKHART DA
      THE INCIDENCE OF GENETIC POLYMORPHISMS OF CYP2C IN A KOREAN POPULATION

      Clinical pharmacology and therapeutics
    52. FLOCKHART DA; RICHARD E; SOUKOVA N; KERBUSCH T
      METABOLISM OF PIMOZIDE BY CYP3A AND CYP2D6 IN HUMAN LIVER-MICROSOMES

      Clinical pharmacology and therapeutics
    53. DONAHUE SR; COLLINS JM; FLOCKHART DA; ABERNETHY DR; TRAPNELL CB
      THALIDOMIDE PHARMACOKINETICS DO NOT CHANGE WITH CHRONIC ADMINISTRATION

      Clinical pharmacology and therapeutics
    54. FLOCKHART DA; DRICI MD; SAMUEL C; ABERNETHY DR; WOOSLEY RL
      OF GENDER ON PROPRANOLOL PHARMACOKINETICS AND PHARMACODYNAMICS

      The FASEB journal
    55. FLOCKHART DA
      DRUG-INTERACTIONS, CARDIAC TOXICITY, AND TERFENADINE - FROM BENCH TO CLINIC

      Journal of clinical psychopharmacology
    56. LARSON C; CAVUTO NJ; FLOCKHART DA; WEINBERG RB
      BIOAVAILABILITY AND EFFICACY OF OMEPRAZOLE GIVEN ORALLY AND BY NASOGASTRIC TUBE

      Digestive diseases and sciences
    57. SALCEDO JA; LEWIS JH; SUKHOVA N; BENJAMIN SB; FLOCKHART DA
      CLARITHROMYCIN INHIBITS OMEPRAZOLE METABOLISM IN HUMAN LIVER-MICROSOMES

      Gastroenterology
    58. MARINAC JS; BALIAN JD; FOXWORTH JW; WILLSIE SK; DAUS JC; OWEN R; FLOCKHART DA
      DETERMINATION OF CYP2C19 PHENOTYPE IN BLACK-AMERICANS WITH OMEPRAZOLE- CORRELATION WITH GENOTYPE

      Clinical pharmacology and therapeutics
    59. BENTON RE; FLOCKHART DA; SALE M; WOOSLEY RL
      INFLUENCE OF GENDER ON QUINIDINE (Q) PHARMACOKINETICS (PK)

      Clinical pharmacology and therapeutics
    60. FLOCKHART DA; RICHARD E; WOOSLEY RL; PEARLE PL; DRICI MD
      A METABOLIC INTERACTION BETWEEN CLARITHROMYCIN AND PIMOZIDE MAY RESULT IN CARDIAC TOXICITY

      Clinical pharmacology and therapeutics
    61. DRICI MD; SALE M; BURNETT A; WOOSLEY RL; FLOCKHART DA
      RR-QT RELATIONSHIPS DIFFER DURING EXERCISE-INDUCED AND ISOPROTERENOL-INDUCED TACHYCARDIA - EFFECT OF BETA-BLOCKADE

      Clinical pharmacology and therapeutics
    62. MARINAC JS; FLOCKHART DA; FOXWORTH JW; WILLSIE SK; DAUS JC; BALIAN JD
      OMEPRAZOLE (OPZ) AS A PROBE FOR THE CYP2C19 POLYMORPHISM IN AN AFRICAN-AMERICAN (AA) POPULATION

      Clinical pharmacology and therapeutics
    63. BALIAN JD; FLOCKHART DA; HARRIS JW
      UTILITY OF THE ACID-LABILE METABOLITE (ALM) OF MEPHENYTOIN (MP) AS A PROBE FOR THE CYP2C19 METABOLIC POLYMORPHISM

      Clinical pharmacology and therapeutics
    64. OWEN R; MACPHERSON A; FLOCKHART DA
      A RAPID METHOD FOR SIMULTANEOUS GENOTYPING OF CYP2D6 A-ALLELE AND B-ALLELE USING THE POLYMERASE CHAIN-REACTION

      Clinical pharmacology and therapeutics
    65. BENTON RE; SALE M; CHEN YW; TRAPNELL CB; FLOCKHART DA; WOOSLEY RL
      WOMEN HAVE GREATER QTC PROLONGATION WITH QUINIDINE THAN MEN

      Circulation
    66. KETTER TA; FLOCKHART DA; POST RM; DENICOFF K; PAZZAGLIA PJ; MARANGELL LB; GEORGE MS; CALLAHAN AM
      THE EMERGING ROLE OF CYTOCHROME-P450 3A IN PSYCHOPHARMACOLOGY

      Journal of clinical psychopharmacology
    67. HADIDI HF; IRSHAID YM; WOOSLEY RL; IDLE JR; FLOCKHART DA
      S-MEPHENYTOIN HYDROXYLATION PHENOTYPES IN A JORDANIAN POPULATION

      Clinical pharmacology and therapeutics
    68. BALIAN JD; SUKHOVA N; HARRIS JW; HEWETT J; PICKLE L; GOLDSTEIN JA; WOOSLEY RL; FLOCKHART DA
      THE HYDROXYLATION OF OMEPRAZOLE CORRELATES WITH S-MEPHENYTOIN METABOLISM - A POPULATION STUDY

      Clinical pharmacology and therapeutics
    69. BALIAN JD; WALDHORN RE; IMPAGNATIELLO F; GUIDOTTI A; WOOSLEY RL; FLOCKHART DA
      FLUMAZENIL EFFECTS ON BREATHING AND ENDOZEPINE LEVELS IN PATIENTS WITH SLEEP-APNEA

      Clinical pharmacology and therapeutics
    70. SALCEDO JA; YASUDA SU; MURPHY MP; WOOSLEY RL; FLOCKHART DA
      STEREOSELECTIVE INHIBITION OF CYP2D6 BY CHLORPHENIRAMINE

      Clinical pharmacology and therapeutics
    71. CHEN Y; FLOCKHART DA; TRAPNELL CB; HALL JE; SALCEDO J; WOOSLEY RL
      A METABOLITE OF PENTAMIDINE BLOCKS HUMAN CARDIAC POTASSIUM CHANNELS

      Clinical pharmacology and therapeutics
    72. CAVUTO NJ; SUKHOVA N; HEWETT J; BALIAN JD; WOOSLEY RL; FLOCKHART DA
      EFFECT OF OMEPRAZOLE ON THEOPHYLLINE CLEARANCE IN POOR METABOLIZERS OF OMEPRAZOLE

      Clinical pharmacology and therapeutics
    73. CLAUW DJ; FLOCKHART DA; MULLINS W; KATZ P; MEDSGER TA
      EOSINOPHILIA-MYALGIA-SYNDROME NOT ASSOCIATED WITH THE INGESTION OF NUTRITIONAL SUPPLEMENTS

      Journal of rheumatology
    74. WOOSLEY RL; FLOCKHART DA
      EVALUATING DRUGS AFTER THEIR APPROVAL FOR CLINICAL USE

      The New England journal of medicine
    75. GUPTA PK; FLOCKHART DA; SOUKHOVA N; FLEISCHER DE; BENJAMIN SB
      OMEPRAZOLE METABOLISM IN PATIENTS WITH REFRACTORY GASTROESOPHAGEAL REFLUX (GER)

      Gastroenterology
    76. LING SM; FLOCKHART DA; WOOSLEY RL; KATZ P
      XENOBIOTIC METABOLISM IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A STUDY OF CYP2D6 GENOTYPE

      Clinical research
    77. BALIAN JD; SUKHOVA N; HEWETT J; HARRIS JW; WOOSLEY RL; FLOCKHART DA
      METABOLITES OF OMEPRAZOLE AS PROBES FOR THE S-MEPHENYTOIN POLYMORPHISM

      Clinical research
    78. CLAUW DJ; HEWETT J; BLANK CA; KATZ P; WOOSLEY RL; FLOCKHART DA
      XENOBIOTIC METABOLISM IN FIBROMYALGIA

      Clinical research
    79. FLOCKHART DA; CLAUW DJ; SALE EB; HEWETT J; WOOSLEY RL
      PHARMACOGENETIC CHARACTERISTICS OF THE EOSINOPHILIA-MYALGIA-SYNDROME

      Clinical pharmacology and therapeutics
    80. LING SM; FLOCKHART DA; WOOSLEY RL; KATZ P
      XENOBIOTIC METABOLISM IN SYSTEMIC LUPUS-ERYTHEMATOSUS - A STUDY OF CYP2D6 GENOTYPE

      Arthritis and rheumatism
    81. CLAUW DJ; HEWETT J; BLANK CA; KATZ P; WOOSLEY RL; FLOCKHART DA
      XENOBIOTIC METABOLISM IN FIBROMYALGIA

      Arthritis and rheumatism
    82. LING SM; FLOCKHART DA; SALE M; WOOSLEY RL; KATZ P
      EVALUATING GENOTYPES FOR CYP-2D6 METABOLIC PATHWAYS IN LUPUS

      Clinical research
    83. CLAUW DJ; FLOCKHART DA; BUCHERT E; HARRIS J; BLANK CA; KATZ P; WOOSLEY RL
      XENOBIOTIC METABOLISM IN THE EOSINOPHILIA-MYALGIA-SYNDROME (EMS)

      Arthritis and rheumatism
    84. CLAUW DJ; FLOCKHART DA; BUCHERT E; HARRIS J; BLANK CA; KATZ P; WOOSLEY RL
      IENOBIOTIC METABOLISM IN THE EOSINOPHILIA-MYALGIA-SYNDROME (EMS)

      Arthritis and rheumatism


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 09/12/19 alle ore 14:28:34